Identifying biomarkers to predict the risk of Barrett's esophagus progressing to cancer or recurring after treatment.
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation
This study is looking for ways to identify which patients with Barrett's esophagus are at low risk of developing cancer so they can avoid unnecessary treatments, while also figuring out which patients might face a higher chance of cancer returning after treatment, all to help doctors take better care of their patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10914984 on NIH RePORTER |
What this research studies
This research focuses on validating molecular biomarkers that can help distinguish between high and low risk cases of Barrett's esophagus, a condition that can lead to esophageal cancer. The study involves two main approaches: a prospective study to identify patients who are at low risk of progression and can avoid unnecessary treatment, and a retrospective study to determine which patients are at risk of recurrence after treatment. By using advanced techniques, the research aims to improve patient management and reduce overtreatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Barrett's esophagus, particularly those with varying degrees of dysplasia.
Not a fit: Patients who do not have Barrett's esophagus or those with advanced esophageal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate risk assessments for patients with Barrett's esophagus, potentially sparing many from unnecessary treatments and associated complications.
How similar studies have performed: Previous research has shown promise in using biomarkers for cancer risk assessment, indicating that this approach could be effective.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Markowitz, Sanford D. — Case Western Reserve University
- Study coordinator: Markowitz, Sanford D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.